Patients CVID | CVID total (n = 16) | HC total (n = 16) |
---|---|---|
Median agea | 34.0 (22–65) | 36 (21–65) |
Gender (male/female) | 10/6 | 7/9 |
Onset of disease (early/late)b | 9/7 | Â |
Autoimmunity manifestations (%) | 19 | Â |
Bronchiectasis (%) | 62.5 | Â |
Splenomegaly (%) | 43.75 | Â |
Lymphadenopathy (%) | 1.5 | Â |
GI symptoms (%) | 25 | Â |
Granulomas (%) | 12.5 | Â |
Cancer (%) | 12.5 | Â |
Median duration of IVIg (years) | 9.0 (3–15) |  |
Immunoglobulin G (mg/dL)c | 771.5 (459–926) |  |
Immunoglobulin A (mg/dL) | 5 (0.2–29.4) |  |
Immunoglobulin M (mg/dL) | 10.2 (1.85–32.4) |  |
B cells (CD3− CD19+) (%) | 6.6 (4.58–10.13) | 30.4 (9.68–40.98) |
Naive B cells (IgD+ CD27−) (%) | 88.9 (75.78–93.60) | 36.65 (31.05–57.50) |
Memory B cells (IgD− CD27+) (%) | 1.63 (0.4–3.4) | 17.75 (11.25–21.20) |